Uniqure NVNASDAQ:QURE
- LAST PRICE5.0800
- TODAY'S CHANGE (%)0.1050 (2.1106%)
- Bid / Lots5.0100/ 10
- Ask / Lots5.1900/ 10
- Open / Previous Close5.0100 / 4.9750
- Day Range
- 52 Week Range
- Volume517,884
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | QURE |
|---|---|---|
| 09:32 ET | 1906 | 5.01 |
| 09:34 ET | 100 | 5.07 |
| 09:39 ET | 1050 | 5.07 |
| 09:43 ET | 200 | 5.095 |
| 09:45 ET | 300 | 5.1 |
| 09:48 ET | 106 | 5.095 |
| 09:52 ET | 1290 | 5.06 |
| 09:54 ET | 300 | 5.05 |
| 09:56 ET | 820 | 5.04 |
| 09:57 ET | 4001 | 5.015 |
| 09:59 ET | 200 | 5 |
| 10:01 ET | 3083 | 5.02 |
| 10:03 ET | 300 | 5.02 |
| 10:06 ET | 1800 | 5.0273 |
| 10:08 ET | 300 | 5.015 |
| 10:10 ET | 1400 | 5.015 |
| 10:12 ET | 1500 | 5.01 |
| 10:14 ET | 100 | 5.01 |
| 10:15 ET | 2400 | 5.015 |
| 10:17 ET | 1800 | 4.99 |
| 10:19 ET | 1200 | 4.99 |
| 10:24 ET | 600 | 4.99 |
| 10:26 ET | 100 | 4.98 |
| 10:28 ET | 400 | 4.99 |
| 10:30 ET | 200 | 4.99 |
| 10:32 ET | 400 | 4.99 |
| 10:35 ET | 300 | 4.995 |
| 10:37 ET | 2000 | 4.99 |
| 10:39 ET | 200 | 4.99 |
| 10:42 ET | 3400 | 5.02 |
| 10:44 ET | 100 | 5.03 |
| 10:46 ET | 100 | 5.02 |
| 10:48 ET | 3577 | 5.05 |
| 10:50 ET | 1846 | 5.05 |
| 10:51 ET | 460 | 5.055 |
| 10:53 ET | 900 | 5.04 |
| 10:55 ET | 2178 | 5.02 |
| 10:57 ET | 500 | 4.995 |
| 11:00 ET | 6296 | 4.99 |
| 11:02 ET | 1251 | 4.99 |
| 11:04 ET | 2489 | 5.03 |
| 11:08 ET | 6622 | 5 |
| 11:09 ET | 1100 | 5.01 |
| 11:13 ET | 400 | 5.02 |
| 11:15 ET | 1509 | 5.03 |
| 11:18 ET | 1631 | 5.06 |
| 11:20 ET | 1100 | 5.07 |
| 11:22 ET | 3291 | 5.09 |
| 11:24 ET | 7663 | 5.11 |
| 11:26 ET | 1325 | 5.11 |
| 11:27 ET | 3004 | 5.1 |
| 11:29 ET | 3637 | 5.13 |
| 11:33 ET | 2668 | 5.15 |
| 11:36 ET | 2112 | 5.12 |
| 11:40 ET | 2623 | 5.115 |
| 11:42 ET | 600 | 5.1 |
| 11:44 ET | 3059 | 5.11 |
| 11:45 ET | 2600 | 5.09 |
| 11:47 ET | 200 | 5.095 |
| 11:49 ET | 1893 | 5.105 |
| 11:51 ET | 1787 | 5.1 |
| 11:54 ET | 100 | 5.105 |
| 11:56 ET | 4940 | 5.1 |
| 12:02 ET | 177 | 5.105 |
| 12:03 ET | 200 | 5.105 |
| 12:05 ET | 1145 | 5.1 |
| 12:09 ET | 1000 | 5.105 |
| 12:12 ET | 400 | 5.1 |
| 12:14 ET | 2437 | 5.1 |
| 12:16 ET | 5699 | 5.08 |
| 12:18 ET | 12119 | 5.08 |
| 12:20 ET | 7303 | 5.04 |
| 12:21 ET | 4877 | 5.055 |
| 12:23 ET | 800 | 5.08 |
| 12:25 ET | 100 | 5.07 |
| 12:27 ET | 100 | 5.08 |
| 12:32 ET | 100 | 5.07 |
| 12:34 ET | 1600 | 5.0621 |
| 12:36 ET | 100 | 5.06 |
| 12:39 ET | 1100 | 5.06 |
| 12:41 ET | 1551 | 5.0517 |
| 12:43 ET | 1954 | 5.03 |
| 12:48 ET | 200 | 5.03 |
| 12:50 ET | 200 | 5.03 |
| 12:52 ET | 100 | 5.03 |
| 12:54 ET | 400 | 5.03 |
| 12:56 ET | 3240 | 5.04 |
| 01:03 ET | 500 | 5.05 |
| 01:06 ET | 2880 | 5.095 |
| 01:08 ET | 100 | 5.095 |
| 01:10 ET | 900 | 5.08 |
| 01:12 ET | 100 | 5.07 |
| 01:14 ET | 301 | 5.075 |
| 01:15 ET | 100 | 5.075 |
| 01:17 ET | 100 | 5.07 |
| 01:19 ET | 500 | 5.08 |
| 01:21 ET | 1000 | 5.1 |
| 01:24 ET | 6400 | 5.095 |
| 01:26 ET | 1000 | 5.11 |
| 01:28 ET | 20879 | 5.13 |
| 01:32 ET | 5560 | 5.16 |
| 01:33 ET | 2004 | 5.1699 |
| 01:35 ET | 1100 | 5.15 |
| 01:37 ET | 300 | 5.15 |
| 01:39 ET | 2407 | 5.12 |
| 01:42 ET | 6690 | 5.11 |
| 01:44 ET | 5249 | 5.11 |
| 01:46 ET | 3800 | 5.11 |
| 01:48 ET | 3479 | 5.13 |
| 01:50 ET | 2200 | 5.1333 |
| 01:51 ET | 200 | 5.135 |
| 01:53 ET | 830 | 5.145 |
| 01:55 ET | 100 | 5.145 |
| 01:57 ET | 300 | 5.145 |
| 02:00 ET | 200 | 5.145 |
| 02:02 ET | 7904 | 5.145 |
| 02:04 ET | 200 | 5.145 |
| 02:06 ET | 200 | 5.145 |
| 02:08 ET | 900 | 5.135 |
| 02:09 ET | 710 | 5.12 |
| 02:11 ET | 1000 | 5.11 |
| 02:13 ET | 2349 | 5.12 |
| 02:15 ET | 1465 | 5.155 |
| 02:18 ET | 100 | 5.155 |
| 02:20 ET | 800 | 5.1451 |
| 02:24 ET | 506 | 5.1401 |
| 02:26 ET | 1000 | 5.12 |
| 02:27 ET | 1300 | 5.12 |
| 02:29 ET | 100 | 5.12 |
| 02:31 ET | 639 | 5.11 |
| 02:33 ET | 3049 | 5.1 |
| 02:36 ET | 100 | 5.1 |
| 02:38 ET | 300 | 5.1 |
| 02:40 ET | 1119 | 5.08 |
| 02:42 ET | 200 | 5.085 |
| 02:44 ET | 758 | 5.09 |
| 02:45 ET | 1437 | 5.1 |
| 02:49 ET | 500 | 5.09 |
| 02:51 ET | 200 | 5.09 |
| 02:54 ET | 3973 | 5.105 |
| 02:56 ET | 400 | 5.1 |
| 02:58 ET | 2216 | 5.11 |
| 03:00 ET | 700 | 5.115 |
| 03:02 ET | 300 | 5.105 |
| 03:03 ET | 100 | 5.105 |
| 03:05 ET | 1100 | 5.11 |
| 03:07 ET | 2340 | 5.12 |
| 03:09 ET | 1748 | 5.1475 |
| 03:12 ET | 3403 | 5.16 |
| 03:14 ET | 790 | 5.16 |
| 03:16 ET | 1199 | 5.16 |
| 03:18 ET | 2240 | 5.14 |
| 03:20 ET | 300 | 5.145 |
| 03:21 ET | 500 | 5.15 |
| 03:23 ET | 980 | 5.15 |
| 03:25 ET | 1526 | 5.145 |
| 03:27 ET | 14727 | 5.135 |
| 03:30 ET | 2331 | 5.145 |
| 03:32 ET | 800 | 5.1575 |
| 03:34 ET | 2902 | 5.13 |
| 03:36 ET | 900 | 5.13 |
| 03:38 ET | 2809 | 5.095 |
| 03:39 ET | 1300 | 5.0975 |
| 03:41 ET | 900 | 5.095 |
| 03:43 ET | 3099 | 5.085 |
| 03:45 ET | 500 | 5.085 |
| 03:48 ET | 2206 | 5.07 |
| 03:50 ET | 1100 | 5.075 |
| 03:52 ET | 2123 | 5.065 |
| 03:54 ET | 20142 | 5.07 |
| 03:56 ET | 2990 | 5.075 |
| 03:57 ET | 11653 | 5.095 |
| 03:59 ET | 46172 | 5.08 |
Sep 23, 2024
DJ UniQure's Fabry Disease Treatment Gets Orphan Drug Designation from FDA, from 7:36AM ET on Monday Sep 23, 2024 by Dow Jones
7:36AM ET on Monday Sep 23, 2024 by Dow JonesuniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease, from 7:05AM ET on Monday Sep 23, 2024 by Dow Jones
7:05AM ET on Monday Sep 23, 2024 by Dow Jones
Sep 20, 2024
DJ uniQure Price Target Maintained With a $28.00/Share by Cantor Fitzgerald, from 12:36PM ET on Friday Sep 20, 2024 by Dow Jones
12:36PM ET on Friday Sep 20, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Uniqure NV | 242.3M | -0.9x | --- |
TScan Therapeutics Inc | 263.3M | -4.8x | --- |
Molecular Partners AG | 172.6M | -2.5x | --- |
Mediwound Ltd | 180.3M | -8.1x | --- |
MeiraGTx Holdings PLC | 322.6M | -2.9x | --- |
Fulcrum Therapeutics Inc | 249.6M | -10.8x | --- |
Company Information
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Contact Information
- Headquarters
- Paasheuvelweg 25aAMSTERDAM, Netherlands 1105 BP
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- David Meek
- Chief Executive Officer, Executive Director
- Matthew Kapusta
- Chief Financial Officer
- Christian Klemt
- Chief Technical Operations Officer
- Amin Abujoub
- Chief Business and Scientific Officer
- Richard Porter
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $242.3M |
|---|---|
Revenue (TTM) | $27.7M |
Shares Outstanding | 48.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.95 |
EPS | $-5.92 |
Book Value | $4.34 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 8.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -872.93% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
